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Resistance to carbapenems is an increasingly encoun-
tered phenomenon in the ICU, complicating empiric
and targeted antimicrobial therapy. Infections due to
carbapenem-resistant microorganisms are characterized
by high morbidity and mortality [1, 2]. Recently, there
has been an increasing interest in rapid detection tech-
niques, based on real time on-demand easy-to-use PCR,
to detect genes responsible for carbapenem resistance.
One of these techniques is the Cepheid Xpert Carba-R
assay, which is able to detect and differentiate five of the
most frequent genes associated with non-susceptibility to
carbapenems in Gram-negative bacteria (blaKPC, blaVIM,
blaOXA-48, blaIMP-1, blaNDM). The diagnostic performance
of this assay seems to be high when compared to
classic microbiological cultures and gene identification
with in-house PCR in a clinical setting, especially in intra-
abdominal infections using samples from rectum or ab-
dominal drainage material [3, 4]. Originally, assays for
screening of patients carrying multidrug-resistant organ-
isms were used to guide infection control programs, to re-
strict access to patients’ health-care zones, or for outbreak
surveillance. However, several studies reported an associ-
ation between detection from surveillance techniques and
subsequent infection etiology, improving the rate of ad-
equate empiric antimicrobial treatment [5].
The Xpert Carba-R assay delivers results in less than
1 hour. It might be argued that the identification of
genes associated with non-susceptibility at the beginning
of therapeutic decision-making, when clinicians are
deciding whether to add carbapenems or not, may lower
the rate of inadequate use of these antimicrobials, to
which resistance rates are continuously increasing. This
application would shift the utility of this technique from
screening to an active part of therapeutic decision-
making. To date, two aspects may limit its application.
First, although it is able to detect five of the most com-
mon genes, clinicians should carefully evaluate which
are the genetic determinants of carbapenem-resistance
in their ICU to optimize diagnostic performance. Sec-
ond, the data came from rectal swabs and material from
abdominal drainage and the clinical usefulness in other
clinical settings should be tested.
Following this road, we may hope to obtain, in the
near future, information on genes associated with resist-
ance to antibiotics by easy-to-use, on-demand tech-
niques before starting therapies and reducing inadequate
empiric treatment to nearly zero.
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